Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
J0efVtkHP2Q30EdB
